<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01357356</url>
  </required_header>
  <id_info>
    <org_study_id>SPC-SER120-DB3-201101</org_study_id>
    <nct_id>NCT01357356</nct_id>
  </id_info>
  <brief_title>Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulations in Patients With Nocturia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Serenity Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Serenity Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of SER120 nasal spray&#xD;
      formulations in patients with nocturia for a total duration of 14 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in # of Mean Nocturic Episodes Per Night</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change was calculated based on the number of mean nocturic episodes per night between baseline through week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants With 50% or Greater in Reduction of Nocturic Episodes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent of participants achieving at least 50% reduction in mean nocturic episode per night during 12 weeks compared to baseline</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">750</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>SER120 (750 ng/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SER120 (750 ng/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SER120 (1000 ng/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SER120 (1000 ng/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SER120 (1500 ng/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SER120 (1500 ng/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER120 (750 ng/day)</intervention_name>
    <arm_group_label>SER120 (750 ng/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER120 (1000 ng/day)</intervention_name>
    <description>SER120 (1000 ng/day)</description>
    <arm_group_label>SER120 (1000 ng/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER120 (1500 ng/day)</intervention_name>
    <arm_group_label>SER120 (1500 ng/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female 50 years or older&#xD;
&#xD;
          -  Nocturia of 6 or more months duration averaging greater than 2 nocturic episode per&#xD;
             night&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CHF&#xD;
&#xD;
          -  Diabetis Insipidus&#xD;
&#xD;
          -  Renal Insufficiency&#xD;
&#xD;
          -  Hepatic Insufficiency&#xD;
&#xD;
          -  Incontinence&#xD;
&#xD;
          -  Illness requiring systemic steroids&#xD;
&#xD;
          -  Malignancy within the past 5 years&#xD;
&#xD;
          -  Sleep Apnea&#xD;
&#xD;
          -  Nephrotic Syndrome&#xD;
&#xD;
          -  Unexplained Pelvic Mass&#xD;
&#xD;
          -  Urinary Bladder Neurological dysfunction&#xD;
&#xD;
          -  Urinary Bladder Surgery or Radiotherapy&#xD;
&#xD;
          -  Pregnant or Breast Feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Serenity R&amp;D</name>
      <address>
        <city>New City</city>
        <state>New York</state>
        <zip>10956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2011</study_first_posted>
  <results_first_submitted>August 25, 2020</results_first_submitted>
  <results_first_submitted_qc>September 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2020</results_first_posted>
  <disposition_first_submitted>November 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>November 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 24, 2015</disposition_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SER120 750 ng</title>
          <description>All participants received SER120 750 ng once daily</description>
        </group>
        <group group_id="P2">
          <title>SER120 1000 ng</title>
          <description>All participants received SER120 1000 ng once daily</description>
        </group>
        <group group_id="P3">
          <title>SER120 1500 ng</title>
          <description>All participants received SER120 1500 ng once daily</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>All participants received Placebo once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="188"/>
                <participants group_id="P3" count="186"/>
                <participants group_id="P4" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="158"/>
                <participants group_id="P4" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat population</population>
      <group_list>
        <group group_id="B1">
          <title>SER120 750 ng</title>
          <description>All participants received SER120 750 ng once daily</description>
        </group>
        <group group_id="B2">
          <title>SER120 1000 ng</title>
          <description>All participants received SER120 1000 ng once daily</description>
        </group>
        <group group_id="B3">
          <title>SER120 1500 ng</title>
          <description>All participants received SER120 1500 ng once daily</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>All participants received Placebo once daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="186"/>
            <count group_id="B2" value="183"/>
            <count group_id="B3" value="179"/>
            <count group_id="B4" value="186"/>
            <count group_id="B5" value="734"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="9.1"/>
                    <measurement group_id="B2" value="66.1" spread="8.9"/>
                    <measurement group_id="B3" value="66.0" spread="9.4"/>
                    <measurement group_id="B4" value="66.0" spread="10.1"/>
                    <measurement group_id="B5" value="66.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="302"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="112"/>
                    <measurement group_id="B5" value="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="155"/>
                    <measurement group_id="B5" value="635"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="160"/>
                    <measurement group_id="B4" value="175"/>
                    <measurement group_id="B5" value="677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in # of Mean Nocturic Episodes Per Night</title>
        <description>Change was calculated based on the number of mean nocturic episodes per night between baseline through week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>SER120 750 ng</title>
            <description>all participants received SER120 750 ng once daily</description>
          </group>
          <group group_id="O2">
            <title>SER120 1000 ng</title>
            <description>all participants received SER120 1000 ng once daily</description>
          </group>
          <group group_id="O3">
            <title>SER120 1500 ng</title>
            <description>all participants received SER120 1500 ng once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>all participants received placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in # of Mean Nocturic Episodes Per Night</title>
          <description>Change was calculated based on the number of mean nocturic episodes per night between baseline through week 12</description>
          <population>Intent to treat population</population>
          <units>nocturic episodes per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="179"/>
                <count group_id="O4" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.07"/>
                    <measurement group_id="O2" value="-1.4" spread="0.07"/>
                    <measurement group_id="O3" value="-1.6" spread="0.07"/>
                    <measurement group_id="O4" value="-1.2" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With 50% or Greater in Reduction of Nocturic Episodes</title>
        <description>Percent of participants achieving at least 50% reduction in mean nocturic episode per night during 12 weeks compared to baseline</description>
        <time_frame>12 weeks</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>SER120 750 ng</title>
            <description>All participants received SER120 750 ng once daily</description>
          </group>
          <group group_id="O2">
            <title>SER120 1000 ng</title>
            <description>all participants received SER120 1000 ng once daily</description>
          </group>
          <group group_id="O3">
            <title>SER120 1500 ng</title>
            <description>all participants received SER120 1500 ng once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>all participants received Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With 50% or Greater in Reduction of Nocturic Episodes</title>
          <description>Percent of participants achieving at least 50% reduction in mean nocturic episode per night during 12 weeks compared to baseline</description>
          <population>Intent to treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="179"/>
                <count group_id="O4" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were collected from the Safety Population, i.e., any patient who had received one dose of study drug and reported an adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>SER120 750 ng</title>
          <description>all participants received SER120 750 ng once daily</description>
        </group>
        <group group_id="E2">
          <title>SER120 1000 ng</title>
          <description>all participants received SER120 1000 ng once daily</description>
        </group>
        <group group_id="E3">
          <title>SER120 1500 ng</title>
          <description>all participants received SER120 1500 ng once daily</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>all participants received Placebo once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="186"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="184"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="188"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="188"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="184"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Serenity Pharmaceuticals</organization>
      <phone>8456396760 ext 17</phone>
      <email>sfein@serenitypharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

